Pharma

Your Article Summary

See Latest Articles

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL? for Fabry Disease with U.S. FDA
Shire, 10/22/09

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application with the U.S. Food and Drug Administration for REPLAGAL, its enzyme replacement therapy for Fabry disease, by the end of the year. The Company also announces that a treatment protocol for REPLAGAL, filed at the request of FDA, has been approved, and that it will support emergency IND requests.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

 See all of Drug/Product Approvals

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09

Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

 See all of Medical Devices/Products